Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-04-2020 | Metastasis | Original Article – Clinical Oncology

Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents

Authors: Ivana Jochmanova, April Melody T. Abcede, Ruby Jane S. Guerrero, Chandy Lou P. Malong, Robert Wesley, Thanh Huynh, Melissa K. Gonzales, Katherine I. Wolf, Abhishek Jha, Marianne Knue, Tamara Prodanov, Naris Nilubol, Leilani B. Mercado-Asis, Constantine A. Stratakis, Karel Pacak

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2020

Abstract

Purpose

Pheochromocytomas/paragangliomas (PHEOs/PGLs) are rare in children with only a few SDHB mutation-related cases. Previous studies on children were conducted in small cohorts. This large set of pediatric patients provides robust data in the evaluation of clinical outcomes.

Methods

Sixty-four pediatric PHEO/PGL patients with SDHB germline mutations were included in the present study. The clinical presentation, disease course, and survival rate were evaluated.

Results

Thirty-eight males and 26 females were diagnosed with PHEO/PGL at a median age of 13 years. The majority of patients displayed norepinephrine hypersecretion and 73.44% initially presented with a solitary tumor. Metastases developed in 70% of patients at the median age of 16 years and were mostly diagnosed first 2 years and in years 12–18 post-diagnosis. The presence of metastases at the time of diagnosis had a strong negative impact on survival in males but not in females. The estimated 5-, 10-, and 20-year survival rates were 100%, 97.14%, and 77.71%, respectively.

Conclusion

The present report has highlighted several important aspects in the management of pediatric patients with SDHB mutations associated-PHEO/PGL. Initial diagnostic evaluation of SDHB mutation carriers should be started at age of 5–6 years with initial work-up focusing on abdominal region. Thorough follow-up is crucial first 2 years post-diagnosis and more frequent follow-ups are needed in years 10–20 post-diagnosis due to the increased risk of metastases. Although this age group developed metastasis as early as 5 years from diagnosis, we have shown that the overall 20-year prognosis and survival are good.

Amar L, Bertherat J, Baudin E et al (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23:8812–8818. https://doi.org/10.1200/JCO.2005.03.1484 CrossRefPubMed

Amar L, Baudin E, Burnichon N et al (2007) Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92:3822–3828. https://doi.org/10.1210/jc.2007-0709 CrossRefPubMed

Armstrong R, Sridhar M, Greenhalgh KL et al (2008) Phaeochromocytoma in children. Arch Dis Child 93:899–904. https://doi.org/10.1136/adc.2008.139121 CrossRefPubMed

Assadipour Y, Sadowski SM, Alimchandani M et al (2017) SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery 161:230–239. https://doi.org/10.1016/j.surg.2016.05.050 CrossRefPubMed

Babic B, Patel D, Aufforth R et al (2017) Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Surgery 161:220–227. https://doi.org/10.1016/j.surg.2016.05.059 CrossRefPubMed

Barontini M, Levin G, Sanso G (2006) Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann NY Acad Sci 1073:30–37. https://doi.org/10.1196/annals.1353.003 CrossRefPubMed

Bausch B, Wellner U, Bausch D et al (2014) Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer 21:17–25. https://doi.org/10.1530/ERC-13-0415 CrossRefPubMed

Baysal BE, Willett-Brozick JE, Lawrence EC et al (2002) Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39:178–183. https://doi.org/10.1136/jmg.39.3.178 CrossRefPubMedPubMedCentral

Beltsevich DG, Kuznetsov NS, Kazaryan AM, Lysenko MA (2004) Pheochromocytoma surgery: epidemiologic peculiarities in children. World J Surg 28:592–596. https://doi.org/10.1007/s00268-004-7134-9 CrossRefPubMed

Benn DE, Gimenez-Roqueplo AP, Reilly JR et al (2006) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91:827–836. https://doi.org/10.1210/jc.2005-1862 CrossRefPubMed

Bissada NK, Safwat AS, Seyam RM et al (2008) Pheochromocytoma in children and adolescents: a clinical spectrum. J Pediatr Surg 43:540–543. https://doi.org/10.1016/j.jpedsurg.2007.10.038 CrossRefPubMed

Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91:4505–4509. https://doi.org/10.1210/jc.2006-0423 CrossRefPubMed

Cascon A, Inglada-Pérez L, Comino-Méndez I et al (2013) Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. Endocr Relat Cancer 20:L1–6. https://doi.org/10.1530/ERC-12-0339 CrossRefPubMed

Choat H, Derrevere K, Knight L, Brown W, Mack EH (2014) SDHB-associated paraganglioma in a pediatric patient and literature review on hereditary pheochromocytoma-paraganglioma syndromes. Case Rep Endocrinol 2014:502734. https://doi.org/10.1155/2014/502734 CrossRefPubMedPubMedCentral

Ciftci AO, Tanyel FC, Senocak ME, Buyukpamukcu N (2001) Pheochromocytoma in children. J Pediatr Surg 36:447–452. https://doi.org/10.1053/jpsu.2001.21612 CrossRefPubMed

Comino-Mendez I, Gracia-Aznárez FJ, Schiavi F et al (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43:663–667. https://doi.org/10.1038/ng.861 CrossRefPubMed

Crona J, Lamarca A, Ghosal S, Welin S, Skogseid B, Pacak K (2019) Genotype-phenotype correlations in pheochromocytoma and paraganglioma. Endocr Relat Cancer. https://doi.org/10.1530/ERC-19-0024 CrossRefPubMed

Darr R, Zöphel K, Eisenhofer G et al (2012) Combined use of 68Ga-DOTATATE and 18F-FDG PET/CT to localize a bronchial carcinoid associated with ectopic ACTH syndrome. J Clin Endocrinol Metab 97:2207–2208. https://doi.org/10.1210/jc.2012-1402 CrossRefPubMed

De Krijger RR, Van Nederveen FH, Korpershoek E, De Herder WW, De Muinck Keizer-Schrama SM, Dinjens WN (2006) Frequent genetic changes in childhood pheochromocytomas. Ann NY Acad Sci 1073:166–176. https://doi.org/10.1196/annals.1353.017 CrossRefPubMed

Ein SH, Shandling B, Wesson D, Filler R (1990) Recurrent pheochromocytomas in children. J Pediatr Surg 25:1063–1065. https://doi.org/10.1016/0022-3468(90)90219-y CrossRefPubMed

Fishbein L, Leshchiner I, Walter V et al (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31:181–193. https://doi.org/10.1016/j.ccell.2017.01.001 CrossRefPubMedPubMedCentral

Gimenez-Roqueplo AP, Favier J, Rustin P et al (2003) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:5615–5621PubMed

Gimenez-Roqueplo AP, Dahia PL, Robledo M (2012) An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 44(5):328–333. https://doi.org/10.1055/s-0031-1301302 CrossRefPubMed

Hensen EF, Bayley JP (2011) Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Fam Cancer 10:355–363. https://doi.org/10.1007/s10689-010-9402-1 CrossRefPubMed

Hescot S, Curras-Freixes M, Deutschbein T et al (2019) Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European network for the study of adrenal tumors retrospective study. J Clin Endocrinol Metab 104:2367–2374. https://doi.org/10.1210/jc.2018-01968 CrossRefPubMed

Jha A, Ling A, Millo C et al (2018) Superiority of (68)Ga-DOTATATE over (18)F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging 45:787–797. https://doi.org/10.1007/s00259-017-3896-9 CrossRefPubMed

Jochmanova I, Wolf KI, King KS et al (2017) SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol 143:1421–1435. https://doi.org/10.1007/s00432-017-2397-3 CrossRefPubMedPubMedCentral

Kaufman BH, Telander RL, van Heerden JA, Zimmerman D, Sheps SG, Dawson B (1983) Pheochromocytoma in the pediatric age group: current status. J Pediatr Surg 18:879–884. https://doi.org/10.1016/s0022-3468(83)80040-2 CrossRefPubMed

King KS, Prodanov T, Kantorovich V et al (2011) Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol 29:4137–4142. https://doi.org/10.1200/JCO.2011.34.6353 CrossRefPubMedPubMedCentral

Kong G, Grozinsky-Glasberg S, Hofman MS et al (2017) Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J Clin Endocrinol Metab 102:3278–3287. https://doi.org/10.1210/jc.2017-00816 CrossRefPubMed

Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) (2017) WHO classification of tumours of endocrine organs WHO/IARC classification of Tumours, 4th edn. International Agency for Research on Cancer, Lyon

Maher ER, Eng C (2002) The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet 11(2347–2354):1. https://doi.org/10.1093/hmg/11.20.2347 CrossRef

Mei L, Khurana A, Al-Juhaishi T, Faber A, Celi F, Smith S, Boikos S (2019) Prognostic factors of malignant pheochromocytoma and paraganglioma: a combined SEER and TCGA databases review. Horm Metab Res 51:451–457. https://doi.org/10.1055/a-0851-3275 CrossRefPubMed

Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466. https://doi.org/10.1056/NEJMoa020152 CrossRefPubMed

Neumann HP, Pawlu C, Peczkowska M (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943–951. https://doi.org/10.1001/jama.292.8.943 CrossRefPubMed

Niemeijer ND, Rijken JA, Eijkelenkamp K et al (2017) The phenotype of SDHB germline mutation carriers: a nationwide study. Eur J Endocrinol 177:115–125. https://doi.org/10.1530/EJE-17-0074 CrossRefPubMed

Pamporaki C, Därr R, Bursztyn M et al (2013) Plasma-free vs deconjugated metanephrines for diagnosis of phaeochromocytoma. Clin Endocrinol (Oxf) 79:476–483. https://doi.org/10.1111/cen.12191 CrossRef

Pham TH, Moir C, Thompson GB et al (2006) Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics 118:1109–1117. https://doi.org/10.1542/peds.2005-2299 CrossRefPubMed

Rijken JA, Niemeijer ND, Corssmit EP, Jonker MA, Leemans CR, Menko FH, Hensen EF (2016) Low penetrance of paraganglioma and pheochromocytoma in an extended kindred with a germline SDHB exon 3 deletion. Clin Genet 89:128–132. https://doi.org/10.1111/cge.12591 CrossRefPubMed

Ross JH (2000) Pheochromocytoma. Special considerations in children. Urol Clin N Am 27:393–402. https://doi.org/10.1016/s0094-0143(05)70088-4 CrossRef

Schovanek J, Martucci V, Wesley R et al (2014) The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer 14:523. https://doi.org/10.1186/1471-2407-14-523 CrossRefPubMedPubMedCentral

Solis DC, Burnichon N, Timmers HJ et al (2009) Penetrance and clinical consequences of a gross SDHB deletion in a large family. Clin Genet 75:354–363. https://doi.org/10.1111/j.1399-0004.2009.01157.x CrossRefPubMedPubMedCentral

Spoudeas HA (ed) (2005) Paediatric endocrine tumours. A multi-disciplinary consensus statement of best practice from a working group convened under the auspices of the BSPED and UKCCSG (rare tumour working groups). Novo Nordisk Ltd, West Sussex

Stackpole RH, Melicow MM, Uson AC (1963) Pheochromocytoma in children Report of 9 case and review of the first 100 published cases with follow-up studies. J Pediatr 63:314–330. https://doi.org/10.1016/s0022-3476(63)80345-5 CrossRefPubMed

Timmers HJ, Kozupa A, Eisenhofer G et al (2007) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92:779–786. https://doi.org/10.1210/jc.2006-2315 CrossRefPubMed

Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, Pacak K (2009) Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 16:391–400. https://doi.org/10.1677/ERC-08-0284 CrossRefPubMedPubMedCentral

Turkova H, Prodanov T, Maly M et al (2016) Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma/paraganglioma: an national institutes of health study. Endocr Pract 22:302–314. https://doi.org/10.4158/EP15725.OR CrossRefPubMed

Vicha A, Musil Z, Pacak K (2013) Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes 20:186–191. https://doi.org/10.1097/MED.0b013e32835fcc45 CrossRefPubMedPubMedCentral

Title: Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents
Authors: Ivana Jochmanova
April Melody T. Abcede
Ruby Jane S. Guerrero
Chandy Lou P. Malong
Robert Wesley
Thanh Huynh
Melissa K. Gonzales
Katherine I. Wolf
Abhishek Jha
Marianne Knue
Tamara Prodanov
Naris Nilubol
Leilani B. Mercado-Asis
Constantine A. Stratakis
Karel Pacak
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Keyword: Metastasis
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03138-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2020

Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation

Precise therapeutic effect of self-assembling gold nanocluster–PTEN complexes on an orthotropic model of liver cancer

Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes

Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry

25-Hydroxy vitamin D deficiency predicts inferior prognosis in mantle cell lymphoma

Predictors of survival and recurrence after primary surgery for cervical metastasis of unknown primary

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials